adjusted alpha = 0.038 [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2012-08-03 16:26 (5076 d 20:42 ago) – Posting: # 9032
Views: 17,606

Dear Detlew!

❝ Where did the αadj.=0.045 came from? Luckily guess? Or some Hermetism?


More an educated guess. With n1 12 and CV 10% a study is already large enough (fixed sample design 98.8% power) and chances to require a second stage are very low. Since Methods C/D allow for stopping in stage 1 with a 90% CI in these methods αemp. ~ αnominal. In Method B we have to pay the penalty and αemp. ~ αadj.. That’s even more pronounced for higher n1 and the same CV (where <0.1% of studies reach stage 2). So why not increase the level of αadj.? 0.045 was a quick-shot – maybe one can even go to close <0.05.

I will try a more realistic example (n1 36, CV 30%; fixed design power 77.2% and 81.6% for n 40). With αadj. 0.0294 Potvin got αemp.: 0.0397 (B) and 0.0477 (C); studies in stage 2: 29.0% (B) and 22.7% (C).
106 sims of Method B with αadj. 0.0380 (= quick-shot obtained from 104 sims) are running…
BTW, where do you think Method B’s 0.0280 came from? :ponder:

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
392 visitors (0 registered, 392 guests [including 17 identified bots]).
Forum time: 13:08 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5